Plasma Brain-Derived-Neurotrophic Factor levels and cognitive function in euthymic bipolar type I patients by Dias, Vasco Videira et al.
MEETING ABSTRACT Open Access
Plasma Brain-Derived-Neurotrophic Factor
levels and cognitive function in euthymic
bipolar type I patients
Vasco Videira Dias
1,5*, Sofia Brissos
1,2, Benicio N Frey
3, Ana Cristina Andreazza
4, Flávio Kapczinski
5,
Maria Luisa Figueira
1
From 1
st International Congress on Neurobiology and Clinical Psychopharmacology and European
Psychiatric Association Conference on Treatment Guidance
Thessaloniki, Greece. 19-22 November 2009
Background
Brain-derived neurotrophic factor (BDNF) is an important
contributor to the pathophysiology of bipolar disorder
(BD), and abnormalities in the BDNF-signaling system
may be implicated in the cognitive decline observed in BD
patients. We aimed to investigate serum BDNF levels in
BD patients, and its relation with neurocognitive function.
Materials and methods
We measured serum BDNF levels using an enzyme-
linked immunosorbent assay method in 65 euthymic
type I BD patients and 50 healthy controls, and adminis-
tered a neuropsychological test battery to assess atten-
tion and mental control, perceptual-motor skills,
executive functions, verbal fluency and abstraction,
visuo-spatial attention, and memory.
Results
We found no significant differences regarding serum
BDNF levels in BD patients and healthy controls. We
found significant positive associations between serum
BDNF levels and illness duration, and manic and depres-
sive episodes in female BD patients only. Serum BDNF
levels were lower in patients medicated with antipsychotics
and/or lithium, whereas patients on valproate and/or anti-
depressants showed higher serum BDNF levels. Patients
performed significantly worse on 11 out of 16 neurocogni-
tive tests as compared to controls. We found a significant
positive association between serum BDNF levels and a test
of verbal fluency in both BD patients and controls.
Conclusions
Present results support the hypothesis that BDNF nor-
malizes with mood stabilization and pharmacological
treatment. Our findings in young and physically healthy
patients, with short illness duration and few mood epi-
sodes may explain the lack of association between
serum BDNF levels and neurocognitive performance,
even though cognitive performance in patients was over-
all significantly worse as compared to healthy controls.
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